imagine

if Europe's Life Sciences Sector:

- Delivered scientific and medical breakthroughs - first.
- Transformed the lives of patients and changed the course of public health.
- Achieved all this, while driving Europe's economic growth, resilience and security.

That is our vision for the future of Europe's life sciences sector.

Why it matters

The life sciences sector is one of Europe's most important strategic assets, delivering innovative medicines and vaccines that are fundamental to the long-term health and security of EU citizens. In recent decades we have seen HIV turned from a death sentence to a condition that can be managed, huge advances in cancer care transforming survival rates, hepatitis C can now be cured in 95% of patients, and there are new tools to stem the tide of the obesity epidemic.

The research-based pharmaceutical industry:

Is responsible for **about 21% of global research** spending

Invests a greater percentage of revenue back into R&D than any other sector

Directly employs around **900,000 people** across Europe and indirectly generates over 2.5 million jobs

At the same time, Europe's life sciences eco-system is facing intense pressure from the US and China where more ambitious, dedicated strategies are driving growth.

Over the last two decades **25% of Europe's share of global R&D investment** has been redistributed to other regions of the world

European biotechs are o**nly able to access around 20% of the finance** that their US counterparts can

Nearly three-quarters of European science graduates choose to remain in the US after completing their doctorates

Why now?

Against a backdrop of continued global insecurity, the EU leaders have underlined the importance of regaining Europe's competitive edge, enhancing our economic security and resilience.

What should the strategy include?

EFPIA calls on EU's policymakers to adopt a new approach to its life sciences ecosystem.

Specifically, that means:

EU STRATEGIC LEADERSHIP executed by a Life Sciences Office

What the EU can do

- Create a Competitiveness Strategy for European Life Sciences and assume strategic leadership guided by a clear vision.
- Establish an EU Office of Life Sciences to ensure policy coordination and regular dialogue with the sector.
- Continuously evaluate the impact of new and existing policies and regulatory proposals on the competitiveness of the EU's life science sector.
- Reduce bureaucratic hurdles that impede innovation and efficiency.

Policies to support the TRANSLATION of ideas into innovation and innovation into products

What the EU can do

- Foster competitive European biotech and pharmaceutical clusters.
- Strengthen European capital markets.
- Upgrade EU's Framework Programmes with fit-for-purpose rules to enable valuable partnerships and build pandemic preparedness.
- Reinforce internationally competitive IP rights.

Building an eco-system for Europe to be THE LOCATION for developing and manufacturing new technologies

What the EU can do

- Address EU skills gaps by improving STEM education, strengthening the EU talent pool and facilitate international talent mobility.
- Develop harmonised, agile, and enabling clinical trials ecosystems that truly support multi-country clinical trials.
- Promote the effective use of health data to fuel research, development and manufacturing of innovative health technologies.
- Attract investment in modern manufacturing through smart regulation.

A commitment to INVEST in health innovation

What the EU can do

- Recognise health expenditure as an investment and set minimum targets for health expenditure.
- Adopt European value-based procurement guidelines that consider broader criteria than price, including environmental standards and supply sustainability.

Policies to secure Europe's future as a GLOBAL biopharma player

What the EU can do

- Ensure robust funding and resources for EMA and the European Medicines Regulatory Network.
- Establish strategic sector-specific open trade and partnership agreements on biotechnology and/or healthcare goods with trusted partner countries.
- Develop new tools and initiatives to attract Foreign Direct Investment in life sciences.
- Ensure full transition to electronic Product Information Leaflets (ePIL) across Member States.

efpia.eu

We've imagined, now let's take action.

efpia